An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390)

Investigational New Drugs

Volumn 15, Issue 2, 1997, Pages 165-172

  Leaf, Andrea N ^a,c   Neuberg, Donna ^b   Schwartz, Edward L ^a,c   Wadler, Scott ^a,c   Ritch, Paul S ^d   Dutcher, Janice P ^a,c   Adams, George L ^e  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Amonafide; Head and neck neoplasms

Indexed keywords

AMONAFIDE; CAFFEINE;

ACETYLATOR PHENOTYPE; ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG ACETYLATION; DRUG EFFICACY; DRUG URINE LEVEL; FATIGUE; FEMALE; HEAD AND NECK CARCINOMA; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LIVER TOXICITY; MALE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; STOMATITIS; THROMBOCYTOPENIA; URINALYSIS; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMIDES; ISOQUINOLINES; MALE; MIDDLE AGED; NAPHTHALIMIDES;

EID: 0030994444     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005823703909     Document Type: Article

References (19)

1. Andersson BS, Bakic M, Beran M, Newman RA, Zwelling LA: Cytotoxic and DNA-cleaving effects of benzisoquinolinedione (nafidimide, NSC 308847] in human leukemia. Proc AACR 27:283, 1986
2. Savaraj N, Liang J, Lu K, Feun LG, Hsu TC: Genotoxicity of [1H]benz (de) isoquinoline-1, 3[2H]dione, 5 amino-2-, [2 (dimethylamino)ethyl] (BIDA) in human lymphocytes. Cancer Invest 7(2):117-121, 1989
3. Nafidimide Clinical Brochure. The National Cancer Institute, Bethesda MD, 1984
4. Kornek G, Raderer M, Depisch D, Haider K, Fazeny B, Dittrich C, Scheithauer W: Amonafide as first-line chemotherapy for metastatic breast cancer. Eur J Cancer 30A(3):398-400, 1994
5. Asbury RF, Blessing JA, Soper JT: A gynecologic oncology group phase II study of amonafide (NSC:308847) in squamous cell carcinoma of the cervix. Am J Clin Oncol 17(2):125-128, 1994
6. Malviya VK, Liu PY, O'Toole R, Alberts DS, Surwit E, Rosenoff S, Ward JH, Yu A, O'Sullivan J, Craig JB: Phase II trial of amonafide in patients with advanced metastatic or recurrent endometrial adenocarcinoma. A southwest oncology group study. Am J Clin Oncol 17(1):37-40, 1994
7. Asbury RF, Blessing JA, Look KY, Clarke-Pearson D, Homesley HD: A gynecologic oncology group phase II study of amonafide (NSC308847) in epithelial ovarian cancer. Am J Clin Oncol 16(6):529-531, 1993
8. Marshall ME, Blumenstein B, Crawford ED, Thompson IM, Craig JB, Eisenberger M, Ahmann F: Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate. A southwest oncology group study. Am J Clin Oncol 17(6):514-515, 1994
9. Berger MZ, Kris MG, Gralla RJ, Marks LD, Potanovich LM, Dimaggio JJ, Heelan RT: Phase II trial of amonafide in patients with stage III and IV non-small cell lung cancer. Am J Clin Oncol 14(2):124-126, 1991
10. Malspeis L, Salam MA, Staubus AE, Lyon ME Grever MR, Balcerzak SP, Leiby JM: Pharmacokinetics and Metabolism of Nafidimide (NSC 308847) in patients following single IV bolus administration. Proc AACR 27:169, 1986
11. Legha SS, Ring S, Raber M, Felder TB, Newman RA, Krakoff IH: Phase I clinical investigation of benzisoquinolinedione. Cancer Treat Rep 71(12):1165-1169, 1987
12. Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Williams SF, Smiddy J: Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther 50:573-579, 1991
13. Felder TB, McLean MA, Vestal ML, Lu K, Farquhar D, Legha SS, Shah R, Newman RA: Pharmacokinetics and metabolism of the antitumor drug Amonafide (NSC-308847) in humans. Drug Metab Dispos 15(6):773-778, 1987
14. Tang BK, Zubovits T, Kalow W: Determination of acetylated caffeine metabolites by high-performance exclusion chromotography. J Chromatogr Biomed Appl 375:170-173, 1986
15. Ratain MJ, Rosner G, Allen SL, Costanza M, Van Echo DA, Henderson IC, Schilsky RL: Population pharmacodynamic study of amonafide: A cancer and leukemia group B study. J Clin Oncol 13(3):741-747, 1995
16. Kilbane AJ, Silbart LK, Manis M, Beitins IZ, Weber WW: Human N-acetylation genotype determination with urinary caffeine metabolites. Clin Pharmacol Ther 47(4):470-477, 1990
17. Hardy BG, Lemieux C, Walker SE, Bartle WR: Interindividual and intraindividual variability in acetylation: Characterization with caffeine. Clin Pharmacol Ther 44:152-157, 1988
18. Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Vogelzang NJ, Lane LB: Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res 53:2304-2308, 1993
19. Wood AJJ, Zhou HH: Ethnic differences in drug disposition and responsiveness. Chin Pharmacokinet 20(5):350-373, 1991